… cases in relation to the use of ustekinumab. … of this study was to evaluate the safety and
efficacy of ustekinumab and anti‐TNF therapy in patients with psoriasis and concomitant chronic …

… and concomitant viral hepatitis remains elusive. We report our clinical experience of
ustekinumab use in patients with concurrent … A retrospective, multicentre study in a clinical setting …

… , although the anti-tumor necrosis factor agents are considered … is safe in clinical practice,
25 reactivation of hepatitis B and C … viral hepatitis B or C: A retrospective, multicentre study in a …

… therapies available in Israel are anti–tumor necrosis factor-α (TNF-α), the interleukin (IL)
12/23 p40 monoclonal antibody ustekinumab, … the safety of using biologics in this setting. The …

… Concomitant hepatitis B virus and hepatitis C virus infections … new HIV-infected cases in
our setting in the last decade, as … and ustekinumab, seem to have an acceptable safety profile …

… The study outcomes indicate that ustekinumab could be safe … of biologic agents including
anti-tumor necrosis factor (TNF)-… of retrospective studies involving psoriasis patients using …

… option for individuals with psoriasis and chronic viral hepatitis. … Safety and efficacy of
anti‐tumor necrosis factors alpha in … viral hepatitis B or C: a retrospective, multicentre study in a …

… retrospective case series of patients infected with hep B and C, who have been treated with
either antitumour necrosis … report about reactivation of hep B virus while on ustekinumab. 1, 2 …

… on the safety of biological therapies in psoriasis patients with … positive patients treated with
anti-tumor necrosis factor (TNF) … with HBV using ustekinumab and secukinumab for psoriasis …

… Nevertheless, safety data are scarce for the use of biologics … with psoriasis treated with
biologics in a real-world setting are … /23 inhibitor (IL-12/23i; ustekinumab), and IL-17 inhibitor (IL-…